Capricor Therapeutics Sued for Securities Fraud Over Alleged Data Misrepresentations

Capricor Therapeutics, Inc. is facing a securities fraud lawsuit over alleged misstatements regarding its drug candidate Deramiocel and the integrity of the clinical data supporting its Biologics License Application (BLA). A prominent securities law firm announced the filing of the complaint against the company.

The lawsuit claims that Capricor Therapeutics made misleading statements about the results of Deramiocel's clinical trials and the reliability of the supporting data. These alleged misrepresentations led to a significant decline in the company's stock value, approximately 64%. The specific timing of the stock drop relative to the alleged misstatements was not detailed but is cited as a consequence.

Deramiocel is an experimental therapy being developed by Capricor Therapeutics for conditions including Duchenne muscular dystrophy and other cardiovascular diseases. The company had submitted a BLA to the U.S. Food and Drug Administration (FDA) for Deramiocel in treating certain cardiovascular conditions. The plaintiff's law firm alleges that company disclosures did not adequately represent the clinical study outcomes and potential risks.

Capricor Therapeutics will now need to respond to these allegations in court. The company is expected to defend its disclosures and the validity of its clinical data. The outcome of the lawsuit could significantly impact the company's future operations and its ability to advance Deramiocel.